<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1673">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04372589</url>
  </required_header>
  <id_info>
    <org_study_id>ATTACC</org_study_id>
    <secondary_id>OZM-113</secondary_id>
    <nct_id>NCT04372589</nct_id>
  </id_info>
  <brief_title>Antithrombotic Therapy to Ameliorate Complications of COVID-19 ( ATTACC )</brief_title>
  <official_title>Antithrombotic Therapy to Ameliorate Complications of COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endothelial injury as a consequence of SARS-CoV-2 infection leads to a dysregulated host
      inflammatory response and activation of coagulation pathways. Macro- and micro-vascular
      thrombosis may contribute to morbidity, organ failure, and death. Therapeutic anticoagulation
      with heparin may improve clinical outcomes in patients with COVID-19 through anti-thrombotic,
      anti-inflammatory, and anti-viral activities of heparins. This pragmatic, Bayesian adaptive
      randomized controlled trial will determine whether therapeutic anticoagulation with heparin
      (subcutaneous low molecular weight heparin or intravenous unfractionated heparin) versus
      usual care reduces the need for intubation or death in hospitalized patients with COVID-19
      not initially requiring invasive mechanical ventilation. The trial uses an adaptive design
      which was chosen to overcome limitations in available data to inform a priori estimation of
      event rates and possible effect sizes. The adaptive design also includes response-adaptive
      randomization based on baseline D-dimer level, probing for differential efficacy across
      subgroups defined based on initial D-dimer level. This Bayesian adaptive randomized trial
      will stop at a conclusion 1) when the posterior probability that the proportional odds ratio
      is greater than 1.0 reaches 99% (definition of benefit); 2) when the posterior probability
      that the proportional odds ratio is greater than 1.2 is less than 10% (definition of
      futility) or; 3) when the posterior probability that the proportional odds ratio is less than
      1.0 is greater than 90% (definition of harm). The trial will enroll a maximum of 3,000
      patients, although in many simulations the trial may require fewer patients. The trial is
      strategically aligned with the international REMAP-CAP/COVID platform trial to accelerate
      evidence generation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open-label, multicentre, Bayesian adaptive randomized clinical trial
      to establish whether therapeutic-dose parenteral anticoagulation improves outcomes for
      patients hospitalized with COVID-19 (e.g., reduces intubation or mortality). Participants
      will be randomized either to the investigational arm (therapeutic anticoagulation with
      heparin for 14 days or until &quot;recovery&quot; [defined as hospital discharge or liberation from
      supplemental oxygen if initially required], whichever comes first), or to the control arm
      (usual care, including thromboprophylactic dose anticoagulation according to local practice).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2020</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Pragmatic, Bayesian adaptive randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intubation and mortality</measure>
    <time_frame>30 days</time_frame>
    <description>The primary endpoint is an ordinal endpoint with three possible outcomes based on the worst status of each patient through day 30: no requirement for invasive mechanical ventilation, invasive mechanical ventilation, or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days and 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intubation</measure>
    <time_frame>30 days</time_frame>
    <description>Invasive mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital-free days</measure>
    <time_frame>30 days</time_frame>
    <description>Days alive outside of the hospital through 30 days following randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU-free days</measure>
    <time_frame>30 days</time_frame>
    <description>Number of days alive outside of the ICU through 30 days following randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days</measure>
    <time_frame>30 days</time_frame>
    <description>Number of days alive without the use of a ventilator through 30 days following randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-invasive ventilation</measure>
    <time_frame>30 days</time_frame>
    <description>The use of non-invasive mechanical ventilation or high flow nasal cannula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ support-free</measure>
    <time_frame>21 days</time_frame>
    <description>Number of days alive without the use of vasopressors/inotropes and ventilation (including high flow nasal cannula &gt;30 L/min and FIO2 &gt;40%) through 21 days following randomization, ranked with death at anytime during 21 days as -1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>30 days and 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischaemic stroke</measure>
    <time_frame>30 days and 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous thromboembolism</measure>
    <time_frame>30 days and 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>Intervention period (maximum 14 days)</time_frame>
    <description>As defined by the International Society on Thrombosis and Haemostasis (ISTH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heparin-induced thrombocytopenia (HIT)</measure>
    <time_frame>Intervention period (maximum 14 days)</time_frame>
    <description>Laboratory-confirmed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>COVID-19</condition>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>Investigational arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to the investigational arm will receive therapeutic anticoagulation for 14 days (or until hospital discharge or liberation from supplemental oxygen &gt;24 hours if previously required, whichever comes first) with heparin, with preference for subcutaneous low molecular weight heparin (enoxaparin preferred, although dalteparin or tinzaparin are also acceptable, as available) if no contraindication is present; alternatively, intravenous unfractionated heparin infusion may be used.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will receive usual care of thromboprophylactic dose anticoagulation according to local practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>Low molecular weight heparin (LMWH) Preferred therapeutic anticoagulant is enoxaparin. Generally regimens: 1.5 mg/kg subcutaneous once daily or 1 mg/kg subcutaneous twice daily. Alternatively, other subcutaneous LMWH used, including tinzaparin (175 anti-Xa IU/kg subcutaneous once daily) or dalteparin (200 IU/kg subcutaneous once daily or 100 IU/kg subcutaneous twice a day).
Unfractionated heparin (UFH) Commenced, administered, and monitored according to local hospital policy, and guidelines that are used for the treatment of venous thromboembolism (i.e. not for acute coronary syndrome). Intravenous infusion of UFH is according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value. If UFH is used, the availability of a local hospital policy that has specifies an aPTT target in this range or an anti-Xa value is a requirement.</description>
    <arm_group_label>Investigational arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Patients ≥18 years of age providing (possibly through a substitute decision maker)
        informed consent who require hospitalization anticipated to last ≥72 hours, with
        microbiologically-confirmed COVID-19, enrolled &lt; 72 hours of hospital admission or of
        COVID-19 confirmation

        Exclusion Criteria:

          1. Receiving invasive mechanical ventilation

          2. Patients for whom the intent is to not use pharmacologic thromboprophylaxis

          3. Active bleeding

          4. Risk factors for bleeding, including:

               1. intracranial surgery or stroke within 3 months;

               2. history of intracerebral arteriovenous malformation;

               3. cerebral aneurysm or mass lesions of the central nervous system;

               4. intracranial malignancy

               5. history of intracranial bleeding

               6. history of bleeding diatheses (e.g., hemophilia)

               7. history of gastrointestinal bleeding within previous 3 months

               8. thrombolysis within the previous 7 days

               9. presence of an epidural or spinal catheter

              10. recent major surgery &lt;14 days

              11. uncontrolled hypertension (sBP &gt;200 mmHg, dBP &gt;120 mmHg)

              12. other physician-perceived contraindications to anticoagulation

          5. Platelet count &lt;50 x10^9/L, INR &gt;2.0, or baseline aPTT &gt;50

          6. Hemoglobin &lt;80 g/L (to minimize the likelihood of requiring red blood cell transfusion
             if potential bleeding were to occur)

          7. Acute or subacute bacterial endocarditis

          8. History of heparin induced thrombocytopenia (HIT) or other heparin allergy including
             hypersensitivity

          9. Current use of dual antiplatelet therapy

         10. Patients with an independent indication for therapeutic anticoagulation

         11. Patients in whom imminent demise is anticipated and there is no commitment to active
             ongoing intervention

         12. Pregnancy

         13. Anticipated transfer to another hospital that is not a study site within 72 hours

         14. Enrollment in other trials related to anticoagulation or antiplatelet therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick R. Lawler, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peter Munk Cardiac Centre/University Health Network</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ewan C. Goligher, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ryan Zarychanski, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ryan Zarychanski, MD, MSc</last_name>
    <phone>204-787-2993</phone>
    <email>rzarychanski@cancercare.mb.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patrick R. Lawler, MD, MPH</last_name>
    <phone>416-340-3155</phone>
    <email>patrick.lawler@uhn.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Paul, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic</name>
      <address>
        <city>Jefferson</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Effron, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Meyer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48336</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Girish Balachandran Nair, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Louis University School of Medicine/Saint Louis Veterans Affairs Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Schoen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Deborah Heart and Lung Center</name>
      <address>
        <city>Browns Mills</city>
        <state>New Jersey</state>
        <zip>08015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent Pompili, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mandeep Sidhu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Health System</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Trivieri, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Robers S. Rosenson, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Montefiore-Einstein Center for Heart and Vascular Care</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mario J Garcia, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aaron Aday, MD, MPH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of São Paulo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Nicolau, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Victoria General Hospital</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Ovakim, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Health Sciences Center Winnipeg</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brett Houstin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grace General Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Glen Drobot, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Boniface General Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vi Dao, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Gross, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Carrier, MD, MSc</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ewan C. Goligher, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Philippe Galanaud, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emily Gibson McDonald, MD, MSc</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'université de Montréal (CHUM)</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuelle Duceppe, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susan Khan, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Vicky Tagalakis, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec-University Laval</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexis Turgeon, MD, MSc</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut universitaire de cardiologie et de pneumologie de Québec (CRIUCPQ)</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francois Lellouche, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regina General Hospital</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Lavolie, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unidad de Investigación en Epidemiología Clínica, Instituto Mexicano del Seguro Social</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jorge Escobedo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Julieta Valenzuela, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eduardo Mateos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 24, 2020</study_first_submitted>
  <study_first_submitted_qc>April 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2020</study_first_posted>
  <last_update_submitted>June 1, 2020</last_update_submitted>
  <last_update_submitted_qc>June 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

